{
  "content": "Abstract\nBackground\nThe optimal pharmacologic means to restore and maintain sinus rhythm in patients with atrial fibrillation remains controversial.\nMethods\nIn this double-blind, placebo-controlled trial, we randomly assigned 665 patients who were receiving anticoagulants and had persistent atrial fibrillation to receive amiodarone (267 patients), sotalol (261 patients), or placebo (137 patients) and monitored them for 1 to 4.5 years. The primary end point was the time to recurrence of atrial fibrillation beginning on day 28, determined by means of weekly transtelephonic monitoring.\nResults",
  "source": "https://www.nejm.org/doi/full/10.1056/NEJMoa041705",
  "chunk_id": "dff3c044-f289-4967-bbd8-522c3b1ebf2a",
  "similarity_score": 0.3834320306777954,
  "query": "atrial fibrillation recurrence rates maintenance therapy amiodarone beta-blockers long-term outcomes rhythm maintenance",
  "rank": 24,
  "title": "Amiodarone versus Sotalol for Atrial Fibrillation",
  "authors": "Bramah N. Singh, M.D., D.Sc., Steven N. Singh, M.D., Domenic J. Reda, Ph.D., X. Charlene Tang, M.D., Ph.D., Becky Lopez, R.N., Crystal L. Harris, Pharm.D., Ross D. Fletcher, M.D., Satish C. Sharma, M.D., J. Edwin Atwood, M.D., Alan K. Jacobson, M.D., H. Daniel Lewis, Jr., M.D., Dennis W. Raisch, Ph.D., Michael D. Ezekowitz, M.B., Ch.B., Ph.D.",
  "year": "2005",
  "journal": "New England Journal of Medicine",
  "reference": "Singh, B. N., Singh, S. N., Reda, D. J., Tang, X. C., Lopez, B., Harris, C. L., Fletcher, R. D., Sharma, S. C., Atwood, J. E., Jacobson, A. K., Lewis, H. D. Jr., Raisch, D. W., & Ezekowitz, M. D. (2005). Amiodarone versus sotalol for atrial fibrillation. New England Journal of Medicine, 352(18), 1861-1872. https://doi.org/10.1056/NEJMoa041705",
  "doi": "10.1056/NEJMoa041705",
  "chunk_index": 4,
  "total_chunks": 127,
  "retrieved_at": "2025-07-24T21:58:13.326259"
}